A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
The purpose of this study is to compare the effectiveness and safety of the study drug, nirogacestat, versus placebo on desmoid tumors.
Progressing Desmoid Tumors/Aggressive Fibromatosis
1. Must be at least 18 years of age
2. Must have clinically confirmed progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Other eligibility criteria will apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Participants will receive the study drug until their disease gets worse or they develop intolerable side effects, this may last for up to 2 years.
An open-label extension will be offered to those participants that qualify.
Knight Cancer Institute Clinical Trials